Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963655 | 1.00 | ALDH1A1 (0.56) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL6889405 | 0.98 | ALDH1A1 (0.55) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL30878143 | 0.98 | ALDH1A1 (0.55) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| SCHEMBL9554893 | 0.89 | ATM (0.53) | ALDH1A1ATMMAPTL3MBTL1TDP1 | |
| Hydrochloric Acid SCHEMBL5090474 | 0.88 | ATM (0.52) | ALDH1A1ATMMAPTL3MBTL1TDP1 | |
| SCHEMBL22692566 | 0.87 | ALDH1A1 (0.58) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| SCHEMBL19357488 | 0.87 | ALDH1A1 (0.50) | ALDH1A1ATML3MBTL1TDP1MAPK1 | |
| SCHEMBL7332996 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| SCHEMBL7363365 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ATMMAPTHPGDHSD17B10 | |
| SCHEMBL6982935 | 0.86 | ALDH1A1 (0.56) | ALDH1A1ATMMAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023108286-A1 | PYRIDOXAL-5-PHOSPHATE (P5P) ANALOGS | CANAM BIORESEARCH INC. (CA) | 2023-06-22 | — | — | WO | disclosed |
| EP-2890704-B1 | 2'-ETHYNYL NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9814739-B2 | 2′-ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| WO-2017098252-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES AND OF THE GEMCITABINE PRODRUG NUC-1031 | NUCANA BIOMED LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9556216-B2 | 2′-Ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160289259-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150232501-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| US-20140065101-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| EP-0537269-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS. | VERTEX PHARMA (US) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289259-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | EIF2AK2, WNK1, OXSR1 | ALDH1A1 2135/4885ATM 2859/4885MAPT 775/4885 |
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | ALDH1A1 1309/4885ATM 3616/4885MAPT 2496/4885 |
| US-20140065101-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | EIF2AK2, WNK1, OXSR1 | ALDH1A1 2135/4885ATM 2859/4885MAPT 775/4885 |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | EIF2AK2, NEK5, ERN2 | ALDH1A1 3720/4885ATM 2945/4885MAPT 1076/4885 |
| US-20150232501-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | EIF2AK2, ERN2, NEK5 | ALDH1A1 3587/4885ATM 2970/4885MAPT 1074/4885 |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | ALDH1A1 1558/4885ATM 1572/4885MAPT 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.